Nuo Therapeutics annual operating margin
2010
2011
2012
2013
2014
2015
2017
2018
2022
2023
2024
2025
Nuo Therapeutics's operating margin was −75.95% for fiscal 2025.
View full Nuo Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −75.95% | +104.09 pp |
| 2024 | 2024-12-31 | −180.04% | +340.61 pp |
| 2023 | 2023-12-31 | −520.65% | +2437.56 pp |
| 2022 | 2022-12-31 | −2,958.21% | −2848.43 pp |
| 2018 | 2018-12-31 | −109.78% | +2044.62 pp |
| 2017 | 2017-12-31 | −2,154.40% | −1795.44 pp |
| 2015 | 2015-12-31 | −358.96% | −57.60 pp |
| 2014 | 2014-12-31 | −301.35% | −144.98 pp |
| 2013 | 2013-12-31 | −156.38% | −34.32 pp |
| 2012 | 2012-12-31 | −122.06% | −73.57 pp |
| 2011 | 2011-12-31 | −48.49% | +89.65 pp |
| 2010 | 2010-12-31 | −138.15% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −9.42% | +83.70 pp |
| Q1 2026 | 2026-03-31 | −34.29% | +119.55 pp |
| Q4 2025 | 2025-12-31 | −52.82% | +106.53 pp |
| Q3 2025 | 2025-09-30 | −52.33% | +103.31 pp |
| Q2 2025 | 2025-06-30 | −93.12% | +55.46 pp |
| Q1 2025 | 2025-03-31 | −153.83% | +148.52 pp |
| Q4 2024 | 2024-12-31 | −159.35% | +171.64 pp |
| Q3 2024 | 2024-09-30 | −155.65% | +184.32 pp |
| Q2 2024 | 2024-06-30 | −148.58% | +588.86 pp |
| Q1 2024 | 2024-03-31 | −302.35% | +1097.31 pp |
| Q4 2023 | 2023-12-31 | −330.99% | +970.61 pp |
| Q3 2023 | 2023-09-30 | −339.97% | +2043.99 pp |
| Q2 2023 | 2023-06-30 | −737.44% | −670.59 pp |
| Q1 2023 | 2023-03-31 | −1,399.66% | −511.07 pp |
| Q4 2022 | 2022-12-31 | −1,301.60% | +258.04 pp |
| Q3 2022 | 2022-09-30 | −2,383.96% | −2403.35 pp |
| Q3 2019 | 2019-09-30 | −66.85% | +91.37 pp |
| Q2 2019 | 2019-06-30 | −888.59% | −467.31 pp |
| Q1 2019 | 2019-03-31 | −1,559.64% | −1142.17 pp |
| Q4 2018 | 2018-12-31 | 19.39% | +4355.13 pp |
| Q3 2018 | 2018-09-30 | −158.21% | +689.64 pp |
| Q2 2018 | 2018-06-30 | −421.28% | +1652.33 pp |
| Q1 2018 | 2018-03-31 | −417.48% | +557.89 pp |
| Q4 2017 | 2017-12-31 | −4,335.74% | −3285.90 pp |
| Q3 2017 | 2017-09-30 | −847.85% | −707.68 pp |
| Q2 2017 | 2017-06-30 | −2,073.61% | −1685.09 pp |
| Q1 2017 | 2017-03-31 | −975.36% | +281.27 pp |
| Q3 2016 | 2016-09-30 | −1,049.84% | −896.59 pp |
| Q1 2016 | 2016-03-31 | −140.16% | −70.48 pp |
| Q4 2015 | 2015-12-31 | −388.51% | −155.57 pp |
| Q3 2015 | 2015-09-30 | −1,256.63% | −990.84 pp |
| Q2 2015 | 2015-06-30 | −153.25% | +269.02 pp |
| Q1 2015 | 2015-03-31 | −69.69% | +182.23 pp |
| Q4 2014 | 2014-12-31 | −232.94% | −122.65 pp |
| Q3 2014 | 2014-09-30 | −265.79% | −128.86 pp |
| Q2 2014 | 2014-06-30 | −422.27% | −229.95 pp |
| Q1 2014 | 2014-03-31 | −251.91% | −36.01 pp |
| Q4 2013 | 2013-12-31 | −110.29% | +61.79 pp |
| Q3 2013 | 2013-09-30 | −136.94% | +102.26 pp |
| Q2 2013 | 2013-06-30 | −192.32% | −128.60 pp |
| Q1 2013 | 2013-03-31 | −215.91% | −125.76 pp |
| Q4 2012 | 2012-12-31 | −172.09% | −180.16 pp |
| Q3 2012 | 2012-09-30 | −239.19% | −171.83 pp |
| Q2 2012 | 2012-06-30 | −63.73% | +25.06 pp |
| Q1 2012 | 2012-03-31 | −90.14% | +18.43 pp |
| Q4 2011 | 2011-12-31 | 8.07% | +107.59 pp |
| Q3 2011 | 2011-09-30 | −67.36% | +68.61 pp |
| Q2 2011 | 2011-06-30 | −88.79% | — |
| Q1 2011 | 2011-03-31 | −108.58% | — |
| Q3 2010 | 2010-09-30 | −99.51% | — |
| Q2 2010 | 2010-06-30 | −135.97% | — |
Over the last five reported fiscal years, Nuo Therapeutics's operating margin increased from −2,154.40% to −75.95%, a change of +2078.45 percentage points. The latest reported quarter, Q2 2026, shows −9.42%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuo Therapeutics filings at SEC.gov ↗